Portal de Periódicos da CAPES

Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis

2014; Nature Portfolio; Volume: 46; Issue: 8 Linguagem: Inglês

10.1038/ng.3013

1546-1718

Jamie Weaver, Caryn S. Ross-Innes, Nicholas B. Shannon, Andy G. Lynch, Tim Forshew, Mariagnese Barbera, Muhammed Murtaza, Chin‐Ann Johnny Ong, Pierre Lao-Sirieix, Mark Dunning, Laura Smith, Mike L. Smith, Charlotte Anderson, Benilton S. Carvalho, Maria O’Donovan, Tim Underwood, Andrew P. May, Nicola Grehan, Richard Hardwick, Jim Davies, Arusha Oloumi, Samuel Aparício, Carlos Caldas, Matthew Eldridge, Paul A. Edwards, Nitzan Rosenfeld, Simon Tavaré, Rebecca C. Fitzgerald,

Gastrointestinal Tumor Research and Treatment

Rebecca Fitzgerald and colleagues used genome sequence analyses to study the progression from premalignant Barrett's esophagus to esophageal adenocarcinoma (EAC) and found that the majority of recurrently mutated genes in EAC were also mutated in precursor lesions and that only mutations in TP53 and SMAD4 were stage specific. Cancer genome sequencing studies have identified numerous driver genes, but the relative timing of mutations in carcinogenesis remains unclear. The gradual progression from premalignant Barrett's esophagus to esophageal adenocarcinoma (EAC) provides an ideal model to study the ordering of somatic mutations. We identified recurrently mutated genes and assessed clonal structure using whole-genome sequencing and amplicon resequencing of 112 EACs. We next screened a cohort of 109 biopsies from 2 key transition points in the development of malignancy: benign metaplastic never-dysplastic Barrett's esophagus (NDBE; n = 66) and high-grade dysplasia (HGD; n = 43). Unexpectedly, the majority of recurrently mutated genes in EAC were also mutated in NDBE. Only TP53 and SMAD4 mutations occurred in a stage-specific manner, confined to HGD and EAC, respectively. Finally, we applied this knowledge to identify high-risk Barrett's esophagus in a new non-endoscopic test. In conclusion, mutations in EAC driver genes generally occur exceptionally early in disease development with profound implications for diagnostic and therapeutic strategies.